Overview

Renal Impairment Study

Status:
Completed

Trial end date:
2019-03-19

Target enrollment:

Participant gender:

Summary

The study will investigate the pharmacokinetics of BAY1142524 in subjects with mild to severe renal impairment compared to age; weight, and gender-matched healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Fulacimstat